Xaluprine 20 mg/ml, Suspension zum Einnehmen

7680653710018 CH-65371 suspension
Xaluprine 20 mg/ml, Suspension zum Einnehmen
Xaluprine 20 mg/ml, Suspension zum Einnehmen
Xaluprine 20 mg/ml, Suspension zum Einnehmen
1 / 3
google

Article details

Package size
100
Selling units
100
Measure
ml
Galenic form
suspension
Galenic group
unbekannt

Official Swissmedic V2 data

Additional information from the official database

Official medical documents

Patient information leaflet
Allemand
16/08/2025
Patient information leaflet
Français
16/08/2025
Patient information leaflet
Italien
16/08/2025
Summary of Product Characteristics
Allemand
15/08/2025
Summary of Product Characteristics
Français
15/08/2025
Summary of Product Characteristics
Italien
15/08/2025

Detailed composition

Substance Quantity Type Category
(N/A)
20.0 MG Substance Wirkstoff (Principe actif)
(N/A)
- Substance HNIDK
(N/A)
3.0 MG Substance HBESI
(N/A)
- Substance HNIDK
(N/A)
- Substance HBESI
(N/A)
- Substance HBESI
(N/A)
1.15 MG Substance HBESI
(N/A)
0.57 MG Substance HBESI
(N/A)
- Substance Konservierungsstoff (Conservateur)
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance HBESI

Reimbursement information

Public price
CHF 292.00
Specialties list
Yes
Generic
No

Reimbursement limitation

SL addition date: 01/06/2025

Authorization holder

Lipomed AG

4144 Arlesheim

Authorization information

Swissmedic authorization number
65371
Drug name
Xaluprine 20 mg/ml, Suspension zum Einnehmen
Galenic form
SUOR
ATC Code
L01BB02
Authorization status
Z
Dispensing category
A
First authorization
18/12/2014
Authorization expiration date
31/12/9999
IT Number
07.16.1.
Domain
Human medicine
Field of application
Zytostatikum

Package details

Description (FR)
XALUPRINE susp 20 mg/ml fl 100 ml
Description (DE)
XALUPRINE Susp 20 mg/ml Fl 100 ml
Market launch
18/12/2014
Narcotic (BTM)
No